<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2826">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04358003</url>
  </required_header>
  <id_info>
    <org_study_id>MH-007/B</org_study_id>
    <nct_id>NCT04358003</nct_id>
  </id_info>
  <brief_title>Plasma Adsorption in Patients With Confirmed COVID-19</brief_title>
  <official_title>Plasma Adsorption in Patients With Confirmed COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marker Therapeutics AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Terumo BCT</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Marker Therapeutics AG</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterize the ability of the D2000 Cartridge in combination with the Optia SPD Protocol
      to reduce the morbidity and mortality associated with SARS-CoV-2 infection in patients
      admitted to the ICU.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Sequential Organ Failure Assessment [SOFA] scores</measure>
    <time_frame>Day 28</time_frame>
    <description>Scale of 0-24 with a higher number indicating a worse outcome</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Respiratory Failure</condition>
  <condition>ARDS</condition>
  <arm_group>
    <arm_group_label>Plasma Adsorption Cartridge</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive one treatment per day with the D2000 Cartridge for use with the Spectra Optia® Apheresis System (Optia SPD Protocol) for up to 4 hours (treatment cycle) for up to seven (7) days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)</intervention_name>
    <description>Subjects will receive one treatment per day with the D2000 Cartridge for up to 4 hours (treatment cycle) for up to seven (7) days. Treatment may extend beyond 7 days, up to 14 days total, if deemed necessary and useful by the principal investigator (PI). Additional cartridges may be used, if needed, to achieve the maximum daily treatment duration of 4 hours. Each day, before initiating the treatment cycle, pre-treatment chemistry and hematology, coagulation status, and disease severity scores (SOFA, APACHE II) will be collected. Then, immediately following the therapy on each treatment day, post-therapy measurements will also be collected.
Study Exit. Subjects will be exited from the study after the Day 28 follow-up visit which will occur 28 days after Study Day 1. Subjects will be included in the study for a total of 28 days. Subjects may also choose to discontinue at any time or conclude participation at the discretion of the PI or the subject's treating physician.</description>
    <arm_group_label>Plasma Adsorption Cartridge</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years old

          -  Admitted to ICU

          -  Diagnosis of SARS-CoV-2 with any one of the following conditions:

               1. Early acute lung injury (ALI)/early acute respiratory distress syndrome (ARDS);
                  or

               2. Severe disease, defined as:

                    1. dyspnea,

                    2. respiratory frequency ≥ 30/min

                    3. blood oxygen saturation ≤ 93%

                    4. partial pressure of arterial oxygen to fraction of inspired oxygen ratio &lt;
                       300, and/or

                    5. lung infiltrates &gt; 50% within 24 to 48 hours; or

               3. Life-threatening disease, defined as:

                    1. respiratory failure,

                    2. septic shock, and/or

                    3. multiple organ dysfunction or failure.

          -  Patient fact sheet is provided to the subject.

          -  Subject or legal representative is able and willing to give informed consent. If
             authorized by the IRB, emergent plasma adsorption with the D2000 cartridge may be
             initiated prior to consent.

        Exclusion Criteria:

          -  Treatment limitation or a do not attempt to resuscitate in place

          -  Pregnancy

          -  Significant or uncontrolled bleeding

          -  In the opinion of the investigator, any other condition that precludes plasma
             adsorption with the D2000
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eeke Romo, MD</last_name>
    <phone>1-877-339-4228</phone>
    <email>eua@markerhealth.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UNM Health Science Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay Raval, MD</last_name>
      <phone>505-925-7765</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Wells, MD</last_name>
      <phone>503-963-3030</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UT Southwestern/Clements Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole De Simone, MD</last_name>
      <phone>214-633-4923</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UTMB</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77550</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean Yates, MD</last_name>
      <phone>409-772-1978</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Medical Campus</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vikramjit Khangoora, MD</last_name>
      <phone>703-776-4001</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 20, 2020</study_first_submitted>
  <study_first_submitted_qc>April 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>August 13, 2020</last_update_submitted>
  <last_update_submitted_qc>August 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Spectra Optia Apheresis System</keyword>
  <keyword>D2000 Cartridge</keyword>
  <keyword>Terumo BCT</keyword>
  <keyword>Marker Therapeutics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coal Tar</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

